A new indication application for Sacituzumab Tirumotecan (sac-TMT) in combination with pembrolizumab as first-line treatment in PD-L1-Negative Non-Squamous NSCLC has been accepted for review by the NMPA. Company announcement - FT.com.
A new indication application for Sacituzumab Tirumotecan (sac-TMT) in combination with pembrolizumab as first-line treatment in PD-L1-Negative Non-Squamous NSCLC has been accepted for review by the NMPA. Company announcement - FT.com.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in